These data suggest that psoriasis catalytic therapy is an effective therapeutic modality for preventing disease rebounding of psoriasis-like skin lesions through ESR1, much better than conventional Cal treatment, in addition to its satisfactory efficacy in the initial treatments. Here, ESR1 is linked to psoriasis.